Abstract
Background Current guidelines recommend placing an implantable cardiac defibrillator for patients with cardiac sarcoidosis (CS) and severely impaired left ventricular ejection fraction (LVEF) of ≤35%. In this study, we aimed to explore the association between mild or moderate LVEF impairment and fatal ventricular arrhythmic event (FVAE).
Methods Here, 401 patients with CS without sustained ventricular arrhythmia at diagnosis were retrospectively analyzed. The primary endpoint was an FVAE, which was defined as the combined endpoint of documented ventricular tachycardia or ventricular fibrillation and sudden cardiac death. Two cut-off points for LVEF were used; sex-specific lower threshold of normal range of LVEF, 52% for men and 54% for women, and LVEF of 35% which is used in the current guidelines.
Results During a median follow-up of 3.2 years, 58 FVAEs were observed, and the 5- and 10-year estimated incidences of FVAE were 16.8% and 23.0%, respectively. All patients were classified into three groups according to LVEF: impaired LVEF group, mild to moderate impairment of LVEF group, and maintained LVEF group. Multivariable competing risk analysis showed that both the impaired LVEF group (HR: 3.02, 95% CI: 1.25–7.32) and the mild to moderate impairment of LVEF group (HR: 2.12, 95% CI: 1.02–4.40) were associated with a higher incidence of FVAE than the maintained LVEF group after adjustment for covariates.
Conclusions Patients with CS are at a high risk of FVAEs, regardless of documented ventricular arrhythmia at the time of diagnosis. In patients with CS, even mild to moderate impairment of LVEF is associated with FVAEs.
What is Known
Patients with cardiac sarcoidosis (CS) are at a higher risk of fatal ventricular arrhythmic event (FVAE).
Current guidelines adopt left ventricular ejection fraction (LVEF) ≤35% as a cut-off value for Class I indication for implantable cardioverter defibrillators (ICD) implantation.
What the Study Adds
Cumulative incidence curves showed that the 5-year FVAE risk in patients with CS with preserved LVEF was 7%, which was as high as that of non-ischemic cardiomyopathy with reduced LVEF.
For risk stratification of future fatal ventricular arrhythmic events, even milder left ventricular ejection fraction impairment, compared to that currently suggested by guidelines, needs to be considered as a risk factor in patients with cardiac sarcoidosis.
Preventive strategies for fatal ventricular arrhythmic events and sudden cardiac death using an implantable cardiac defibrillator according to individualized risk stratification need to be developed and evaluated in clinical studies of patients with cardiac sarcoidosis.
Competing Interest Statement
Dr. Yuya Matsue received an honorarium from Otsuka Pharmaceutical Co and Novartis Japan. Dr. Takahiro Okumura received honoraria from Ono Yakuhin, Otsuka, Novartis, and Astrazeneca, as well as research grants from Ono Yakuhin, Amgen Astellas, Pfizer, Alnylam, and Alexion (not in connection with the submitted work). Other authors have nothing to declare.
Funding Statement
The ILLUMINATE-CS study was partially supported by Novartis Pharma Research Grants, and this research was partially supported by AMED under Grant Number JP21ek0109543 and JSPS KAKENHI (Grant Number 22K16147).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the ethics committee of each participating hospital, and the requirement for informed consent was waived because of the retrospective nature of the study. Study information, including the objectives, inclusion and exclusion criteria, and names of participating hospitals, was published in the publicly available University Hospital Information Network (UMIN000034974).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data not available due to ethical restrictions.
Abbreviations
- CS
- cardiac sarcoidosis
- SCD
- sudden cardiac death
- ICD
- implantable cardioverter defibrillators
- AHA/ACC/HRS
- American Heart Association/American College of Cardiology/Heart Rhythm Society
- JCS
- Japanese Circulation Society
- LVEF
- left ventricular ejection fraction
- VT/VF
- ventricular tachycardia and ventricular fibrillation
- LGE
- late gadolinium enhancement
- CMR
- cardiac magnetic resonance
- IQR
- interquartile range
